-
Mashup Score: 4Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer - 6 month(s) ago
An expanded indication for dostarlimab plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer is under EMA review.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer - 6 month(s) ago
An expanded indication for dostarlimab plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer is under EMA review.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer #gyncsm #oncology https://t.co/tubvMsioje
-
-
Mashup Score: 2Next Steps With Pembrolizumab/Lenvatinib in Endometrial Cancer - 6 month(s) ago
Christian Marth, MD, PhD, discusses next steps with pembrolizumab and lenvatinib for use in the advanced or recurrent endometrial cancer treatment paradigm.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Christian Marth, MD, PhD, discusses implications of the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer and other research efforts of interest. #Gyncsm #Oncology https://t.co/fp1WnaKrfp
-
-
Mashup Score: 2Adjuvant Pembrolizumab/Chemo Misses Primary End Point of DFS in High-Risk Endometrial Cancer - 7 month(s) ago
Adjuvant treatment with pembrolizumab plus chemotherapy did not improve DFS vs placebo plus chemotherapy in high-risk endometrial cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Adjuvant Pembrolizumab/Chemo Misses Primary End Point of DFS in High-Risk Endometrial Cancer #gyncsm #oncology https://t.co/OcVtB1S3yh
-
-
Mashup Score: 2Adjuvant Pembrolizumab/Chemo Misses Primary End Point of DFS in High-Risk Endometrial Cancer - 7 month(s) ago
Adjuvant treatment with pembrolizumab plus chemotherapy did not improve DFS vs placebo plus chemotherapy in high-risk endometrial cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Adjuvant Pembrolizumab/Chemo Misses Primary End Point of DFS in High-Risk Endometrial Cancer #gyncsm #oncology https://t.co/OcVtB1S3yh
-
-
Mashup Score: 5New $15 Million Grant to Dana-Farber Scientists Supports Research into Innovative Approaches to Endometrial Cancer Treatment - 7 month(s) ago
Physician-scientists at Dana-Farber Cancer Institute have received a 5-year, $15 million Program Project Grant from the NCI for research in endometrial cancer
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
New $15 Million Grant to Dana-Farber Scientists Supports Research into Innovative Approaches to Endometrial Cancer Treatment @DanaFarberNews #gyncsm #oncology https://t.co/DM2ngJBhJB
-
-
Mashup Score: 2Adjuvant Pembrolizumab/Chemo Misses Primary End Point of DFS in High-Risk Endometrial Cancer - 8 month(s) ago
Adjuvant treatment with pembrolizumab plus chemotherapy did not improve DFS vs placebo plus chemotherapy in high-risk endometrial cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Adjuvant Pembrolizumab/Chemo Misses Primary End Point of DFS in High-Risk Endometrial Cancer #gyncsm #oncology https://t.co/OcVtB1S3yh
-
-
Mashup Score: 1Efficacy and Safety Data With Pembrolizumab/Lenvatinib in LEAP-001 of Endometrial Cancer - 8 month(s) ago
Christian Marth, MD, PhD, discusses efficacy and safety findings from the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Hear from Christian Marth, MD, PhD, as he discusses efficacy and safety findings from the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer. #gyncsm #oncology https://t.co/Pzj2PvC4WD
-
-
Mashup Score: 3
Keiichi Fujiwara, MD, PhD, discusses the significance of the FDA approval of tisotumab vedotin for patients with recurrent or metastatic cervical cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
WATCH: Dr Fujiwara on the @us_fda Approval of Tisotumab Vedotin for Recurrent Cervical Cancer #gyncsm #oncology https://t.co/UqB0NFRLsC
-
-
Mashup Score: 5Improved Molecular Classification Drives Tailored Treatment Approaches in Endometrial Cancer - 8 month(s) ago
Abdulrahman Sinno, MD, discusses the paradigm shift from a histology-based to molecular-based understanding of endometrial cancer and its impact on treatment outcomes.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Improved Molecular Classification Drives Tailored Treatment Approaches in Endometrial Cancer @SylvesterCancer #gyncsm #oncology https://t.co/oaTohc6vqs
-
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer #gyncsm #oncology https://t.co/tubvMsioje